SecBot SecBot

Cancer Drug Parity Act of 2025

H.R. 4101 Rep. Glenn Grothman (R-WI-6) In committee
Bill text PDF
  1. Introduced Jun 24
  2. Committee Jun 24
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jun 24, 2025Next: House vote
491d ago Jun 24, 2025: Referred to the House Committee on Education and Workforce.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
3trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

This bill requires group health plans that cover anticancer medications given by a healthcare provider to also cover oral anticancer drugs with no less favorable cost-sharing. It applies to plan years starting on or after January 1, 2026. Sec. 2, Parity in cost-sharing for oral anticancer drugs: A group health plan covering intravenously administered or injected anticancer medications must ensure that cost-sharing for FDA-approved, patient-administered oral anticancer drugs is no less favorable. This applies only if the treating physician finds the oral medication medically necessary or clinically appropriate. Plans cannot increase out-of-pocket costs, reclassify benefits to raise costs, or impose stricter limits on oral anticancer drugs than on injected ones. The section does not require replacing other anticancer drugs with oral ones, does not prohibit prior authorization, and does not override stronger state laws. Cost-sharing includes deductibles, coinsurance, copayments, and out-of-pocket maximums. Sec. 3, GAO study: Within two years of enactment, the Comptroller General must study the impact of the new parity requirement on out-of-pocket costs for oral anticancer drugs, comparing plans subject to the requirement with those not subject to it, and submit a report to Congress with recommendations to reduce financial barriers to access.

Summary of the bill text as introduced in House (Jun 24, 2025), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.